Showing 3811-3820 of 6035 results for "".
- Novaliq and BLP Management Group Establish New Company, Betaliq, to Leverage EyeSol Technology to Treat Glaucomahttps://modernod.com/news/novaliq-and-blp-management-group-establish-new-company-betaliq-to-leverage-eyesol-technology-to-treat-glaucoma/2476500/Novaliq and BLP Management group announced the formation and funding of Betaliq. The Tampa-based company’s pipeline consists of two preservative-free glaucoma drug candidates based on new in class and best in class ß-blocker molecules using Novaliq’s waterfree EyeSol technology. Two EyeSol-
- James Mazzo Joins Board of Directors at Avellino Labshttps://modernod.com/news/james-mazzo-joins-board-of-directors-at-avellino-labs/2476451/Avellino Labs announced the strategic addition of James V. Mazzo to its board of directors. The partnership will further anchor Avellino Lab’s leadership in developing the science and setting the standard of genetic testing in ophthalmology, according to a company news release.
- Improved Premium IOLs Will Drive Growth in the Global IOL Market Over the Next 5 Yearshttps://modernod.com/news/improved-premium-iols-will-drive-growth-in-the-global-iol-market-over-the-next-5-years/2476449/Innovation in premium lens technology will fuel patient demand in the global IOL market over the next 5 years, according to a Market Scope report. The improved technology will provide better visu
- IStent Inject Device Lowers IOP After Cataract Surgery in Glaucoma Patientshttps://modernod.com/news/istent-inject-device-lowers-iop-after-cataract-surgery-in-glaucoma-patients/2476438/In patients with mild to moderate glaucoma and cataract, the second-generation iStent inject system, with two redesigned stents, reduces IOP more than cataract surgery alone, according to results of a new pivotal trial, as reported by Reut
- Lightmed and Mexico’s Leading Pediatric Hospitals Partner in Childhood Blindness Preventionhttps://modernod.com/news/lightmed-and-mexicos-leading-pediatric-hospitals-partner-in-childhood-blindness-prevention/2476428/Lightmed Corp. announced the successful installation and support of 34 LIGHTLas 810 photocoagulator lasers across 32 Mexican states. Mexico’s Ministry of Health initially purchased 18 Lightmed lasers to be placed in areas with the most urgent need. Soon after, they ordered an additional 16 units
- Higher Calcium Intake Tied to Slower AMD Progressionhttps://modernod.com/news/higher-calcium-intake-tied-to-slower-amd-progression/2479580/Higher levels of dietary and supplementary calcium intake are associated with a lower risk of progression to late age-related macular degeneration (AMD), according to a secondary analysis of data from a large trial, as reported by Reuters.
- Johnson & Johnson Vision Announces Availability of Acuvue Oasys With Transitions Light Intelligent Technology in the U.S.https://modernod.com/news/johnson-johnson-vision-announces-availability-of-acuvue-oasys-with-transitions-light-intelligent-technology-in-the-u-s/2479584/Johnson & Johnson Vision announced the US availability of Acuvue Oasys with Transitions Light Intelligent Technology. The contact lenses adapt to changing light, helping eyes recover from bright light up to 5 seconds faster, reducing halos and starbursts at night, and delivering more sight w
- I-PEN Osmolarity System Now Available in Brazil Through Partnership with DryComhttps://modernod.com/news/i-pen-osmolarity-system-now-available-in-brazil-through-partnership-with-drycom/2476420/The I-PEN is the world’s first, point-of-care, electronic diagnostic testing device to detect and indirectly measure the tear film osmolarity levels associated with marginal, mild, moderate and severe dry eye disease. The I-PEN Osmolarity System, used in conjunction with the I-PEN Osmolarity Sing
- 5% People Tested Positive at Free Initial Screenings for Glaucoma at Saifee Hospitalhttps://modernod.com/news/5-people-tested-positive-at-free-initial-screenings-for-glaucoma-at-saifee-hospital/2476400/Saifee Hospital, one of Mumbai’s leading multi-specialty hospitals, conducted almost 400 free eye check-ups for their visitors to observe World Glaucoma Week. The check-ups were conducted throughout the week and more than 20 people were detected to have high
- Aerpio Pharmaceuticals Does Not Meet Primary Endpoint in Phase 2b Study for Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-does-not-meet-primary-endpoint-in-phase-2b-study-for-diabetic-retinopathy/2476386/Aerpio Pharmaceuticals announced topline results from the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). Administration o